17 Amendments of Pietro FIOCCHI related to 2020/2076(INI)
Amendment 17 #
Motion for a resolution
Citation 21 a (new)
Citation 21 a (new)
- having regard to the Commission Communication of 2 June 2020 on the Roadmap of the Pharmaceutical Strategy – timely patient access to affordable medicines,
Amendment 215 #
Motion for a resolution
Paragraph 6
Paragraph 6
6. Calls on the Commission to include in the recovery plan a strategy to redeploystrengthen European industries in Europe and globally, and to relocate industrial production in strategic sectors that are not already resilient or global leaders, in a WTO-compliant way; calls, moreover, on the Commission to adopt a stronger stance on unfair global competition and predatory acquisitions by SOEs and sovereign funds; is of the opinion that, in this context, the Union should implement a provisional TDI scheme;
Amendment 224 #
Motion for a resolution
Paragraph 6 a (new)
Paragraph 6 a (new)
6a. Stresses the importance of the Union maintaining a secure supply of medicines and medical equipment; recalls that 76,6% of active pharmaceutical ingredients for on-patent products are already sourced from within Europe, with 11.9% from the US and only 9% from Asia (including Japan and South Korea);
Amendment 228 #
Motion for a resolution
Paragraph 6 b (new)
Paragraph 6 b (new)
6b. Calls on the Commission to preserve a vibrant research-based pharmaceutical industry on its territory, considering that the EU remains by far the first manufacturing region of active pharmaceutical ingredients for on-patent medicines;
Amendment 391 #
Motion for a resolution
Paragraph 13
Paragraph 13
13. Highlights the potential of the circular economy for modernising the Union’s economy, reducing its energy and resource consumption and transforming whole industrial sectors and their value chains, with a view to guaranteeing all sectors of the economy appropriate support during this transformation phase;
Amendment 416 #
Motion for a resolution
Paragraph 14
Paragraph 14
14. Considers that there is significant potential in domestic and global markets for low-emission technologies and sustainable products, processes and services throughout the whole value chain from raw materials to energy-intensive industries, manufacturing and the industrial services sector and to the many MSMEs involved in developing green technologies, products and services; considers, moreover, that the Climate Law is a first step towards enshrining climate targets into Union legislation; believes that a more holistic and systematic target framework is also required in order to ensure policy coherence across all Union policies and a homogenous governance approach in all policy areas, paving the way towards a clear and stable strategy for European industries;
Amendment 451 #
Motion for a resolution
Paragraph 15
Paragraph 15
15. Maintains that a truly effective European industrial policy needs a dashboard of climate targets as a roadmap to shape the industry of the future; considers that all sectors should contribute towards achieving the Union’s climate objectives and, in this regard, underlines the importance of scaling up research and technological development as key factors underpinning the transition and of gas as a means of energy transition and hydrogen as a potential breakthrough technology; calls also for greater attention to be paid to network security and energy supply; calls on the Council to increase spending from the EU budget on climate change efforts; calls on the Commission to ensure that industries with high carbon leakage do not benefit from EU subsidies, and for better use to be made of the EIB, as the Union’s ‘Climate Bank’, to enhance sustainable financing to the public and private sectors and to assist companies in the decarbonisation process, and to use the Border Carbon Adjustments mechanism as a way to protect EU manufacturers and jobs from unfair international competition;
Amendment 534 #
Motion for a resolution
Paragraph 17 a (new)
Paragraph 17 a (new)
17a. Calls on the Commission to revive and update the ideas underpinning the Small Business Act by introducing initiatives designed to support in particular micro- and small enterprises, which make up more than 99% of the EU's manufacturing fabric; takes the view that 'one-size-fits-all' initiatives for SMEs do not foster the right approach towards MSMEs and that the broadening of the scope of many measures to cover mid-caps has thrown that mismatch into sharper relief; considers that backing for MSMEs must also take the form of support for the incremental innovation which is typical of enterprises of this kind;
Amendment 562 #
Motion for a resolution
Paragraph 18 a (new)
Paragraph 18 a (new)
18a. Takes the view that incentives to use tax credit schemes must be accompanied by determined action to address fiscal dumping, which distorts the European single market;
Amendment 606 #
Motion for a resolution
Paragraph 20
Paragraph 20
20. Considers that industrial transformation requires the integration of new knowledge and innovation into existing markets and their use in the creation of new ones; regrets, in this respect, that the Union invests less in R&D as a percentage of GDP than its global competitors and that it suffers from a serious lack of innovative capacity in small and medium-sized enterprises due to a shortfall in the necessary risk capital; calls on the Commission to improve the incentives and increase the budget for those programmes that underpin the transformation of the Union’s industry, including Horizon Europe, and to foster synergies between regional, national, European and private financial sources by taking advantage of synergies among all Union programmes;
Amendment 617 #
Motion for a resolution
Paragraph 20 a (new)
Paragraph 20 a (new)
20a. Calls on the Commission to address in its next pharmaceutical and industrial strategies measures focused on ensuring that Europe ‘remains an innovator and world leader’, as outlined in President von der Leyen’s mission letter to Commissioner for health Stella Kyriakides;
Amendment 624 #
Motion for a resolution
Paragraph 20 b (new)
Paragraph 20 b (new)
20b. Acknowledges the importance of research and innovation, and calls for the establishment of a genuine European network to support high quality medical research in Europe;
Amendment 626 #
Motion for a resolution
Paragraph 20 c (new)
Paragraph 20 c (new)
20c. Stresses the need to ensure parity with the US and China in life science IP incentives in order for Europe to remain an attractive location for R&D investment and industrial development; calls on the Commission to maintain and develop Europe’s world-class IP system by promoting strong IP protection, incentives and reward mechanisms for R&D to attract investment into the development of future innovation for the benefit of patients;
Amendment 628 #
Motion for a resolution
Paragraph 20 d (new)
Paragraph 20 d (new)
20d. Acknowledges that the research- based pharmaceutical industry is an essential sector and contributor to ensuring quality manufacturing and supply of medicines to reach all patients in need, to ensuring future innovation to address outstanding, unmet needs, and to supporting the resilience, responsiveness and readiness of healthcare systems to address future challenges including pandemics; acknowledges that the pharmaceutical sector critically employs some 765,000 people in Europe, supports around 2.7 million jobs in the EU, and is the largest contributor to Europe’s positive trade balance, contributing over EUR 91 billion in 2018;
Amendment 647 #
Motion for a resolution
Paragraph 21 a (new)
Paragraph 21 a (new)
21a. Calls on the Commission to create a High-Level Forum on Better Access to Health Innovation with relevant stakeholders, Member States and the Commission in light of their respective competence areas, to develop multi- stakeholder solutions to introducing new technologies into health systems and reduce the time patients in Europe wait for access to new treatments; stresses that a High-Level Forum would furthermore enable a comprehensive discussion and analysis of the root causes of unequal patient access and supply of medicines, also taking into consideration the fragmentation of the EU single market and different national approaches to pricing and reimbursement as well as healthcare investment and organisation;
Amendment 697 #
Motion for a resolution
Paragraph 24 a (new)
Paragraph 24 a (new)
24a. Acknowledges that a strong framework of intellectual property rights is a crucial factor underpinning European competitiveness, and therefore calls on the Commission to preserve and strengthen this framework;
Amendment 698 #
Motion for a resolution
Paragraph 24 b (new)
Paragraph 24 b (new)
24b. In order to protect European competitiveness; insists that the measures proposed in the Commission’s upcoming Pharmaceutical Strategy should be focused on ensuring that Europe ‘remains an innovator and world leader’, as outlined in President von der Leyen’s mission letter to Commissioner Stella Kyriakades, acknowledging that the start of any EU policy aiming at bringing back manufacturing of medicines and active ingredients in Europe starts with the maintenance of a vibrant research-based pharmaceutical industry on its territory;